We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Quest Diagnostics Stock Gains 49.3% YTD: What's Behind the Rally?
Read MoreHide Full Article
Key Takeaways
Quest Diagnostics shares have gained 49.3% YTD, outperforming its industry and the S&P 500.
Quest Diagnostics benefits from physician and hospital revenue growth and wider health plan access.
Quest Diagnostics advances growth through acquisitions, automation, AI and higher EPS guidance.
Quest Diagnostics (DGX - Free Report) shares have rallied 49.3% so far this year, reflecting strong returns. The stock has outperformed the industry’s 28.9% gain, as well as the S&P 500 composite’s rise of 5.9%.
Carrying a Zacks Rank #3 (Hold) at present, the renowned clinical laboratory is benefiting from stronger physician and hospital channel revenues, wider health plan access and continued demand for consumer health services. Advanced Diagnostics is gaining traction, with double-digit growth across several key testing areas. Quest Diagnostics is also pursuing inorganic growth opportunities to strengthen its hospital outreach and independent laboratory businesses.
Headquartered in Secaucus, NJ, Quest Diagnostics provides diagnostic information services to a broad range of customers within its primary channels of physicians, hospitals, patients and consumers. The company is a key provider of reference testing for approximately half of U.S. hospitals. It also offers physician services that are reimbursed by Medicare under a physician fee schedule, which is subject to annual adjustment. Quest Diagnostics has grown mainly through strategic acquisitions and seeks to drive operational excellence across the customer value chain and its operations.
Factors Favoring DGX’s Growth
The rally in the share price can be linked to the company’s expanding service offerings, improved health care access and strategic collaborations. Quest Diagnostics continues to address the needs of physicians, hospitals and consumers through broader access, clinical innovation and integrated service offerings. In the third quarter of 2026, physician channel revenues increased in the high single-digit range, supported by commercial execution and growth in regions where the company expanded health plan access and completed acquisitions.
Hospital channel revenues grew at a double-digit rate, mainly driven by Co-Lab Solutions with Corewell Health. Consumer health continues to benefit from demand for preventive testing and wellness solutions.
Image Source: Zacks Investment Research
Quest Diagnostics is also expanding Advanced Diagnostics across cardiometabolic and endocrine, autoimmune, brain health, oncology and women's and reproductive health. Several key tests in advanced cardiometabolic, hormone and Alzheimer's disease testing delivered double-digit revenue growth in third-quarter 2026. In oncology, New York State's approval of Haystack MRD enables commercial expansion across all 50 states. The company has also integrated selected cancer tests with Flatiron Health's OncoEMR platform, with a pilot involving American Oncology Network intended to support wider access.
The company’s long-term strategy targets 1%-2% annual revenue growth from acquisitions, with an emphasis on hospital outreach assets and independent laboratories. In January 2026, Quest Diagnostics and Corewell Health formed a Michigan laboratory joint venture owned 51% by Quest and 49% by Corewell. Last year, it acquired select clinical testing assets from Fresenius Medical Care's Spectra Laboratories. Together, these are expected to contribute approximately 3% points to the company’s consolidated 2026 revenue growth.
Operationally, the company is expanding automation and artificial intelligence across laboratory and administrative processes to offset labor inflation, improve quality and increase efficiency. Adjusted operating margin increased 40 basis points (bps) year over year to 16.7% in the third quarter. DGX also raised full-year adjusted earnings per share (EPS) guidance to $11.25-$11.35 from $11.05-$11.25 and expects operating margin expansion over 2025.
Concerns for DGX
Quest Diagnostics remains exposed to reimbursement uncertainty, health policy changes and rising operating costs. Preliminary PAMA rates could reduce total revenues by approximately 1% in 2027, with a cumulative impact of less than 1.3% through 2029. While the company is advocating for the RESULTS Act and plans cost offsets, legislative relief remains uncertain.
A Glance at Estimates for DGX
The Zacks Consensus Estimate for Quest Diagnostics’ EPS is projected to increase 14.6% to $11.29 in 2026 and another 5.4% to $11.90 in 2027. In the past seven days, the consensus mark for the 2026 EPS has risen 1 cent.
Revenues for 2026 are projected to grow 9.5% to $12.08 billion, followed by a 4.1% jump to $12.57 billion in 2027.
Bausch + Lomb has an estimated long-term growth rate of 40.1% compared with the industry’s 15.2% growth. Shares of the company have rallied 37.3% compared with the industry’s 4.8% gain over the past year. BLCO’s earnings outpaced estimates in two of the trailing four quarters, matched once and missed on another occasion, the average surprise being 21.67%.
Insulet, sporting a Zacks Rank #1, has an estimated long-term growth rate of 19.4% compared with the industry’s 9.3% gain. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 17.43%. PODD shares have dipped 58.6% compared with the industry’s 21.4% decline over the past year.
IDEXX Laboratories, carrying a Zacks Rank #2 (Buy), has an earnings yield of 2.2% against the industry’s negative 2.3% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 5.5%. IDXX shares have dropped 5% against the industry’s 0.9% growth over the past year.
Image: Bigstock
Quest Diagnostics Stock Gains 49.3% YTD: What's Behind the Rally?
Key Takeaways
Quest Diagnostics (DGX - Free Report) shares have rallied 49.3% so far this year, reflecting strong returns. The stock has outperformed the industry’s 28.9% gain, as well as the S&P 500 composite’s rise of 5.9%.
Carrying a Zacks Rank #3 (Hold) at present, the renowned clinical laboratory is benefiting from stronger physician and hospital channel revenues, wider health plan access and continued demand for consumer health services. Advanced Diagnostics is gaining traction, with double-digit growth across several key testing areas. Quest Diagnostics is also pursuing inorganic growth opportunities to strengthen its hospital outreach and independent laboratory businesses.
Headquartered in Secaucus, NJ, Quest Diagnostics provides diagnostic information services to a broad range of customers within its primary channels of physicians, hospitals, patients and consumers. The company is a key provider of reference testing for approximately half of U.S. hospitals. It also offers physician services that are reimbursed by Medicare under a physician fee schedule, which is subject to annual adjustment. Quest Diagnostics has grown mainly through strategic acquisitions and seeks to drive operational excellence across the customer value chain and its operations.
Factors Favoring DGX’s Growth
The rally in the share price can be linked to the company’s expanding service offerings, improved health care access and strategic collaborations. Quest Diagnostics continues to address the needs of physicians, hospitals and consumers through broader access, clinical innovation and integrated service offerings. In the third quarter of 2026, physician channel revenues increased in the high single-digit range, supported by commercial execution and growth in regions where the company expanded health plan access and completed acquisitions.
Hospital channel revenues grew at a double-digit rate, mainly driven by Co-Lab Solutions with Corewell Health. Consumer health continues to benefit from demand for preventive testing and wellness solutions.
Image Source: Zacks Investment Research
Quest Diagnostics is also expanding Advanced Diagnostics across cardiometabolic and endocrine, autoimmune, brain health, oncology and women's and reproductive health. Several key tests in advanced cardiometabolic, hormone and Alzheimer's disease testing delivered double-digit revenue growth in third-quarter 2026. In oncology, New York State's approval of Haystack MRD enables commercial expansion across all 50 states. The company has also integrated selected cancer tests with Flatiron Health's OncoEMR platform, with a pilot involving American Oncology Network intended to support wider access.
The company’s long-term strategy targets 1%-2% annual revenue growth from acquisitions, with an emphasis on hospital outreach assets and independent laboratories. In January 2026, Quest Diagnostics and Corewell Health formed a Michigan laboratory joint venture owned 51% by Quest and 49% by Corewell. Last year, it acquired select clinical testing assets from Fresenius Medical Care's Spectra Laboratories. Together, these are expected to contribute approximately 3% points to the company’s consolidated 2026 revenue growth.
Operationally, the company is expanding automation and artificial intelligence across laboratory and administrative processes to offset labor inflation, improve quality and increase efficiency. Adjusted operating margin increased 40 basis points (bps) year over year to 16.7% in the third quarter. DGX also raised full-year adjusted earnings per share (EPS) guidance to $11.25-$11.35 from $11.05-$11.25 and expects operating margin expansion over 2025.
Concerns for DGX
Quest Diagnostics remains exposed to reimbursement uncertainty, health policy changes and rising operating costs. Preliminary PAMA rates could reduce total revenues by approximately 1% in 2027, with a cumulative impact of less than 1.3% through 2029. While the company is advocating for the RESULTS Act and plans cost offsets, legislative relief remains uncertain.
A Glance at Estimates for DGX
The Zacks Consensus Estimate for Quest Diagnostics’ EPS is projected to increase 14.6% to $11.29 in 2026 and another 5.4% to $11.90 in 2027. In the past seven days, the consensus mark for the 2026 EPS has risen 1 cent.
Revenues for 2026 are projected to grow 9.5% to $12.08 billion, followed by a 4.1% jump to $12.57 billion in 2027.
Key Picks
Some better-ranked stocks in the broader medical space are Bausch + Lomb Corp. (BLCO - Free Report) , Insulet (PODD - Free Report) and IDEXX Laboratories (IDXX - Free Report) .
Bausch + Lomb has an estimated long-term growth rate of 40.1% compared with the industry’s 15.2% growth. Shares of the company have rallied 37.3% compared with the industry’s 4.8% gain over the past year. BLCO’s earnings outpaced estimates in two of the trailing four quarters, matched once and missed on another occasion, the average surprise being 21.67%.
BLCO sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Insulet, sporting a Zacks Rank #1, has an estimated long-term growth rate of 19.4% compared with the industry’s 9.3% gain. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 17.43%. PODD shares have dipped 58.6% compared with the industry’s 21.4% decline over the past year.
IDEXX Laboratories, carrying a Zacks Rank #2 (Buy), has an earnings yield of 2.2% against the industry’s negative 2.3% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 5.5%. IDXX shares have dropped 5% against the industry’s 0.9% growth over the past year.